Research and Markets (http://www.researchandmarkets.com/research/rkh9lh/pancreatic) has announced the addition of the "Pancreatic Endocrine Tumor - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Pancreatic Endocrine Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. List of Tables
  2. List of Figures
  3. Introduction
  4. REPORT COVERAGE
  5. Pancreatic Endocrine Tumor Overview
  6. Therapeutics Development
  7. Pipeline Products for Pancreatic Endocrine Tumor - Overview
  8. Pipeline Products for Pancreatic Endocrine Tumor - Comparative Analysis
  9. Pancreatic Endocrine Tumor - Therapeutics under Development by Companies
  10. Pancreatic Endocrine Tumor - Pipeline Products Glance
  11. Late Stage Products
  12. Clinical Stage Products
  13. Early Stage Products
  14. Pancreatic Endocrine Tumor - Products under Development by Companies
  15. Pancreatic Endocrine Tumor - Companies Involved in Therapeutics Development
  • Ipsen S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • MediaPharma s.r.l.
  • Novartis AG
  • Tyrogenex, Inc.

For more information visit http://www.researchandmarkets.com/research/rkh9lh/pancreatic